NASDAQ:CYRX - US2290503075 - Common Stock
We assign a fundamental rating of 4 out of 10 to CYRX. CYRX was compared to 55 industry peers in the Life Sciences Tools & Services industry. CYRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CYRX has a correct valuation and a medium growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 8.7% | ||
ROE | 13.06% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | 33.22% | ||
GM | 45.73% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.36 | ||
Debt/FCF | N/A | ||
Altman-Z | 0.58 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 16.24 | ||
Quick Ratio | 15.47 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 6.66 | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
8.86
+0.17 (+1.96%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 6.66 | ||
Fwd PE | N/A | ||
P/S | 2.19 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.86 | ||
P/tB | 1.26 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 8.7% | ||
ROE | 13.06% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | 33.22% | ||
GM | 45.73% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.36 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 68.5% | ||
Cap/Sales | 10.37% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 16.24 | ||
Quick Ratio | 15.47 | ||
Altman-Z | 0.58 |